Libra Infusions (DHA:LIBRAINFU) ROE %: 0.00% (As of . 20)


DHA:LIBRAINFU Libra Infusions Ltd DHA:LIBRAINFU
20 GF Score
Price BDT646.70
View Full Analysis

What is Libra Infusions ROE %?

Libra Infusions DHA:LIBRAINFU +0.67% 20 ROE % is 0.00% as of . 20. GuruFocus rates DHA:LIBRAINFU with a GF Score™ of 20/100. Among 798 Medical Devices & Instruments companies, Libra Infusions ranks worse than 125313.16% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Libra Infusions's annualized net income for the quarter that ended in . 20 was BDT Mil. Libra Infusions's average Total Stockholders Equity over the quarter that ended in . 20 was BDT Mil. Therefore, Libra Infusions's annualized ROE % for the quarter that ended in . 20 was %.

The historical rank and industry rank for Libra Infusions's ROE % or its related term are showing as below:

DHA:LIBRAINFU's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.41
* Ranked among companies with meaningful ROE % only.

Libra Infusions  (DHA:LIBRAINFU) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*( / )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= ( / ) * ( / ) * ( / ) * ( / ) * ( / )
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= * * % * *
= %

Note: The net income data used here is one times the annual (. 20) net income data. The Revenue data used here is one times the annual (. 20) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Libra Infusions ROE % Related Terms


Libra Infusions ROE % Historical Data

* Premium members only.

The historical data trend for Libra Infusions's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Libra Infusions ROE % Chart

Libra Infusions Annual Data
Trend
ROE %

Libra Infusions Semi-Annual Data
ROE %

DHA:LIBRAINFU vs SECI, LENSF, ASNB: ROE % Comparison

For the Medical Instruments & Supplies subindustry, Libra Infusions's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Libra Infusions ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Libra Infusions's ROE % distribution charts can be found below:

* The bar in red indicates where Libra Infusions's ROE % falls into.


DHA:LIBRAINFU
20GF Score
Libra Infusions Ltd DHA:LIBRAINFU
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Libra Infusions ROE % Calculation

Libra Infusions's annualized ROE % for the fiscal year that ended in . 20 is calculated as

ROE %=Net Income (A: . 20 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

Libra Infusions's annualized ROE % for the quarter that ended in . 20 is calculated as

ROE %=Net Income (Q: . 20 )/( (Total Stockholders Equity (Q: . 20 )+Total Stockholders Equity (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Libra Infusions (DHA:LIBRAINFU) has a ROE % of 0.00% as of . 20. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Libra Infusions and its competitors. According to the industry distribution chart, Libra Infusions ranks #999999 out of 798 companies in the Medical Devices & Instruments industry.
Is Libra Infusions' ROE % too high?
Libra Infusions' current ROE % is 0.00%. Based on the distribution chart, Libra Infusions ranks #999999 out of 798 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Libra Infusions has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Libra Infusions' ROE % compare to SECI and LENSF?
According to the Medical Devices & Instruments industry distribution chart, Libra Infusions ranks #999999 out of 798 companies for ROE %. This places Libra Infusions in the lower half of its industry. The industry median ROE % is 2.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.41, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Libra Infusions and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Libra Infusions's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Libra Infusions stock overvalued right now?
Libra Infusions (DHA:LIBRAINFU) has a current ROE % of 0.00%. The current ROE % is 0.00%. Libra Infusions' overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Libra Infusions (DHA:LIBRAINFU), the current ROE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Libra Infusions Business Description

Address I/7, Mirpur Industrial Estate, Rupnagar, Section-2, Dhaka, BGD, 1216
Libra Infusions Ltd is engaged in manufacturing intravenous fluids. It provides products which are used for medical purposes involving surgical operations, loss of blood, weakness, and general hospitalization.
20GF Score

Get the complete analysis for DHA:LIBRAINFU

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT646.70
Price